Navigation Links
American Liver Foundation Hails Promise of Cure Signaled by FDA's Approval of New Hepatitis C Treatments
Date:12/10/2013

NEW YORK, Dec. 10, 2013 /PRNewswire/ -- The American Liver Foundation fully welcomes FDA approval of two new treatments for Hepatitis C, one of which is a new class of drug. This liver disease affects approximately 3.2 million people in the United States, and roughly 75% of those infected are unaware they carry the virus. Often referred to as a silent epidemic, those infected include baby boomers that may have contracted the virus from surgeries, blood transfusions, and other contaminated blood products before the disease was known to exist.

Sovaldi, known generically as Sofosbuvir, is the first polymerase inhibitor to be approved for treatment of Hepatitis C, in combination with other anti-virals. Olysio, known generically as Simeprevir, is the first once-daily protease inhibitor to be approved. 

"This is the beginning of a new, gentler, era in the treatment of Hepatitis C," states Tom Nealon, National Board Chair of the American Liver Foundation. "We know that thousands of patients have been awaiting new, less invasive, treatment options, and this is exciting news, but we are concerned that millions of cases of infections remain undetected and therefore untreated. These new treatments give hope to existing patients, and strengthen the case for systematically screening all baby boomers," he adds. 

New data from the manufacturers of these and other new drugs for Hepatitis C was presented at the recent AASLD conference in Washington DC, indicating that there are many more new treatments in the pipeline, and promising the possibility of cure. 

"With these new treatments just approved, and many more being developed, we have every reason to be optimistic about the potential to cure and even eradicate this deadly virus," states Hillel Tobias, MD, a liver transplant specialist and Co-Chair of the American Liver Foundation's National Medical Advisory Committee. "With these new treatments, it may be possible to lower the overall cost of treatment due to less side effects and hospitalizations that occurred from previous treatments. If we identify and treat patients with these new medications, it will be possible to prevent the need for many thousands of liver transplants," he adds. 

Both newly approved drugs promise shorter duration of treatment and reduced side-effects, with treatment regimens for some strains of Hepatitis C no longer requiring injections of Interferon, which has been the mainstay of treatment for many years, but is associated with some challenging side effects which can impact a person's ability to work outside the home.

Between 3 and 4 million Americans are infected with Hepatitis C. Many of them are baby boomers who contracted the virus before Hepatitis C was known to exist, in the decades before the commencement of identification and screening in 1992. Other risk factors include tattoos, body piercings, and intravenous drug use.

Left untreated, Hepatitis C leads to liver cirrhosis and liver failure. 75% of patients do not know they have the disease, and 90% do not get treated. The American Liver Foundation hopes that awareness of these new, better-tolerated treatments will bring increased Hepatitis C screenings, testing and treatments.

Additional Resources:

ABOUT THE AMERICAN LIVER FOUNDATION
The American Liver Foundation's (ALF) mission is to facilitate, advocate and promote education, support and research for the prevention, treatment and cure of liver disease. It carries out its mission through education to promote liver health and disease prevention. Three national core programs are targeted to reach the public, at-risk groups, and patients with liver disease. ALF is the leading source of information on liver health and liver disease, through printed materials and www.liverfoundation.org. A toll-free national HelpLine at (800) GO-LIVER and 16 chapters across the country provide support to newly diagnosed patients, families, and the general public, through phone, email, and community outreach. It funds research that has helped to begin the careers of more than 750 scientists in the field of liver health in hopes of finding treatments and cures that will lead to a world free of liver disease. ALF is on twitter at @liverUSA


'/>"/>
SOURCE The American Liver Foundation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ambit Announces Presentations At The 55th Annual Meeting Of The American Society Of Hematology (ASH)
2. Array BioPharma Provides Clinical Update On ARRY-614 For Myelodysplastic Syndromes At The 2013 American Society Of Hematology Meeting
3. Array BioPharma Provides Clinical Update On Filanesib (ARRY-520) For Multiple Myeloma At The 2013 American Society of Hematology Meeting
4. Encouraging Clinical Data From Multicenter Phase 1/2 Trial On Actiniums Actimab-A Presented At American Society Of Hematology Annual Meeting
5. American Pacific To Release Financial Results And Hold Fiscal 2013 Year-End And Fourth Quarter Investor Teleconference
6. Actinium Pharmaceuticals Announces Additional Clinical Data From Multicenter Phase 1/2 Trial on Actiniums Actimab-A to Be Presented at American Society of Hematology Annual Meeting
7. LipiGesic M stands alone among over-the-counter migraine medications based on recently released American Headache Society recommendations
8. Artikel im American Journal of Cardiology zeigt gute Gefäßheilung nach MiStent-SES-Implantation
9. Paper Published in American Journal of Cardiology Demonstrates Favorable Vascular Healing Following MiStent SES Implantation
10. Humacyte Presents Interim First-in-Human Data For Investigational Bioengineered Blood Vessel at the American Heart Association (AHA) Scientific Sessions 2013
11. New data from UCBs epilepsy portfolio to be highlighted at the 67th Annual Meeting of the American Epilepsy Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2017)... , Aug. 4, 2017 The search for ... after a physician/patient consult has long been the goal ... a notable focus of the largest meeting of lab ... to healthcare market research firm Kalorama Information.  The firm ... (POCT) offerings or related supplies and software were at ...
(Date:8/2/2017)... Fenita J. Caldwell is ... Lifetime Professional in the Field of Healthcare. Caldwell ... Pharmaceuticals, AG. Her skills and areas of expertise ... Fenita ... experience as a highly successful sales specialist in ...
(Date:8/2/2017)... CaryRx, a next-generation full-service pharmacy, has announced the launch of ... Washington D.C. metropolitan area. CaryRx aims ... medications through the convenience of its patient-friendly mobile app. Prescriptions ... hour to any location in D.C. ... to Washington D.C. ," says Areo Nazari ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... August 18, 2017 , ... ... campaign, advocating for active, healthy lifestyles and highlighting the importance of proactive eye ... hearing impairments and shares the latest innovations in hearing aid technology. , ...
(Date:8/18/2017)... ... August 18, 2017 , ... Hernandez Insurance Agencies, a northern ... the greater DC region, is inaugurating a “New Leash On Life” charity initiative ... training them to be companions for veterans in need. , The Semper K9 ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... and financial planning firm that serves residential and commercial clients in the greater ... drive to raise community support for the fight against cancer. , Founded by ...
(Date:8/18/2017)... ... , ... Alcovit, a lime-flavored beverage that rids the body of toxins linked ... now available through Jet.com. , After 25 years of development, the company released ... to quickly detox the body thereby avoiding alcohol-induced hangovers. Whether you’re having fun with ...
(Date:8/18/2017)... ... ... Narrow Roads”: a vivid and provocative look into the narrow path toward god. “Three ... currently the pastor-teacher-visionary at Simply the WORD Church, a global prayer ministry and the ... towards youth. , King shares, “When I take time to think about the character ...
Breaking Medicine News(10 mins):